@article {Saad2020.10.28.20221416, author = {Ali A. Saad and Malak Saad and Emad M. Boctor}, title = {COVID-19 Active Surveillance Simulation Case Study - Health and Economic Impacts of Active Surveillance in a School Environment}, elocation-id = {2020.10.28.20221416}, year = {2020}, doi = {10.1101/2020.10.28.20221416}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The COVID-19 pandemic has affected the lives of almost all human beings and has forced stay-at-home mandates across the world. Government and school officials are facing challenging decisions on how to start the new 2020/2021 school year. Almost every school system has chosen a remote learning model for the Fall of 2020 while many are facing financial and logistical challenges.In this study, we explore the efficacy of an Active Surveillance testing model where a random number of students are tested daily for early detection of asymptomatic patients and for prevention of the infection among the student population. In addition to health impacts, we also analyze the financial impact of deploying the Active Surveillance system in schools while taking into consideration lost workdays of parents, hospitalization costs, and testing costs.Under the given assumptions, initial modeling results indicate that low Active Surveillance testing rates (between 6-10\% daily testing of student population) can help achieve low infection rates (<=10\%) among students along with enforcing mitigation procedures, such as wearing masks and social distancing. Without enforcing mitigation procedures, the optimal Active Surveillance rate of 8-10\% can also achieve (<=10\%) infection rates among student population. The results also demonstrate that Active Surveillance can lower the financial burden of the pandemic by proactively lowering the infection rates among student populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive funds from any third party.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB was needed for this work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A}, URL = {https://www.medrxiv.org/content/early/2020/11/03/2020.10.28.20221416}, eprint = {https://www.medrxiv.org/content/early/2020/11/03/2020.10.28.20221416.full.pdf}, journal = {medRxiv} }